Holen Sie sich die Stockscreener-App
24.29
13.72%
2.93
Vorhandelsmarkt:
25.95
1.66
+6.83%
Schlusskurs vom Vortag:
$21.36
Offen:
$21.72
24-Stunden-Volumen:
41.99M
Relative Volume:
1.25
Marktkapitalisierung:
$5.54B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
46.52
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+25.27%
1M Leistung:
-1.94%
6M Leistung:
-61.30%
1J Leistung:
-17.55%
1-Tages-Spanne:
$21.28
$24.70
1-Wochen-Bereich:
$18.96
$24.70
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.29 | 4.87B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Providers Can't Duck Suit Over Student's Suicide - Law360
Allbirds, Hims & Hers, Microsoft, Xanadu Quantum And Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Why Is HIMS Stock Surging More Than 11% After-Hours Today? - Stocktwits
A Look at Hims & Hers Health Inc (HIMS) After 13.7% Gain -- GF V - GuruFocus
Investors Purchase Large Volume of Call Options on Hims & Hers Health (NYSE:HIMS) - MarketBeat
Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides - MarketWatch
Hims Jumps as RFK Jr. Seeks to Loosen Peptide Regulations - Bloomberg.com
Applauding FDA's Move Towards Regulatory Clarity on Peptide Therapy - Hims & Hers Newsroom
FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides - Seeking Alpha
Hims & Hers Health stock gains as ZAVA and Livewell acquisitions boost international sales - Traders Union
Why is Hims & Hers Health stock up today? - Traders Union
Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes - Seeking Alpha
Hims Didn't Protect Customer Data From Hackers, Suit Says - Law360
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms - The Globe and Mail
Modest gains for Hims & Hers Health stock as $21.38 resistance remains in focus - Traders Union
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims & Hers Health Inc (HIMS) Shares Surge 8.8% -- What GF Score of 76 Tells Investors - GuruFocus
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026 - The Joplin Globe
Hers to Announce First Quarter 2026 Financial Results on May 11, 2026 - HIMS Investor Relations
Hims & Hers schedules May 11 earnings release, 5 p.m. ET call - Stock Titan
Hims & Hers Health (HIMS) jumps 9.8% as GLP-1 partnership momentum returns to focus - Quiver Quantitative
Hims & Hers Health stock rises as sellers remain in control of the short-term trend - Traders Union
Okta breach chain hits Hims & Hers in wider ShinyHunters attack spree - Cybernews
Why Hims & Hers Health, Inc. (HIMS) Surged On Friday - MSN
Hims & Hers Health, Inc. Class A Trade Ideas — LS:A2QMYY - TradingView
A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot - Yahoo Finance
Hims And Hers Confronts Amazon Threat While Advancing AI Weight Loss Plan - Yahoo Finance
Hims & Hers (NYSE: HIMS) CEO makes 845,866-share bona fide gift - Stock Titan
HIMS Stock Jumps Premarket: CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce - Stocktwits
Hims Breach Exposes the Most Sensitive Kinds of PHI - Dark Reading
Hims & Hers Health stock price forecast: $21.38 resistance in focus as HIMS drops 1.87% - Traders Union
Why Is HIMS Stock Down 40%? - Trefis
Did Hims & Hers Just Become an AI Company? - The Globe and Mail
Liquidity Mapping Around (HIMS) Price Events - Stock Traders Daily
Investor relations - HIMS Investor Relations
2 Profitable Stocks with Exciting Potential and 1 We Ignore - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Encourages Hims & Hers Health - The National Law Review
Hims & Hers (HIMS) Stock Plummets 39% Amid GLP-1 Strategy Shift and Margin Pressure - MEXC
Why Is HIMS Stock Slipping Premarket Today? - Stocktwits
Hims & Hers (HIMS) Stock Down 39% as GLP-1 Brand Transition Squeezes Margins - CoinCentral
Hims & Hers’ Shift to Branded Obesity Drugs Pressures Stock — Will the Bet Pay Off? - TipRanks
Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration - Sahm
Hims & Hers Health stock rises as FDA-approved Wegovy and Ozempic come back to market - Traders Union
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Hims & Hers Health Is No Longer What The Market Thinks (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. Jumps 5.5% Amid Sector-Wide Selling - AlphaStreet
BofA cuts Hims and Hers stock price target on EBITDA concerns - Investing.com
Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path - Sahm
Hims & Hers Health, Inc. (HIMS) Shares Decline as Broader Market Advances: Important Details - Bitget
Okupe, Hims & Hers health CFO, sells $79k in shares - Investing.com India
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):